Adenoma, Islet Cell D007516

Related MeSH Hierarchy (6)

Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Glandular and Epithelial » Adenoma » Adenoma, Islet Cell

Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Digestive System Neoplasms » Pancreatic Neoplasms » Adenoma, Islet Cell

Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Endocrine Gland Neoplasms » Pancreatic Neoplasms » Adenoma, Islet Cell

Diseases [C] » Digestive System Diseases [C06] » Digestive System Neoplasms » Pancreatic Neoplasms » Adenoma, Islet Cell

Diseases [C] » Digestive System Diseases [C06] » Pancreatic Diseases » Pancreatic Neoplasms » Adenoma, Islet Cell

Diseases [C] » Endocrine System Diseases [C19] » Endocrine Gland Neoplasms » Pancreatic Neoplasms » Adenoma, Islet Cell

Description

A benign tumor of the pancreatic ISLET CELLS. Usually it involves the INSULIN-producing PANCREATIC BETA CELLS, as in INSULINOMA, resulting in HYPERINSULINISM.   MeSH

Hierarchy View

View MeSH Tree View ICD-10 Tree

Subtype Terms (1)

Insulinoma
22 drugs (15 approved, 7 experimental)


Phase 2 Indicated Drugs (14)

bortezomib (velcade)

capecitabine (xeloda)

cisplatin (platinol)

doxorubicin (Doxil)

everolimus (zortress)

Imetelstat

interferon alpha-2b (Intron-A)

irinotecan (Camptosar)

melphalan (alkeran)

octreotide (sandostatin)

pasireotide (signifor)

streptozotocin

sunitinib (sutent)

thalidomide (Thalomid)

Phase 1 Indicated Drugs (1)

y90 edotreotide


Organization Involved with Phase 4 Indications (3)

Novartis

Pfizer

University of Ulsan

Organization Involved with Phase 3 Indications (7)

Federation Francophone de Cancerologie Digestive

Genentech

Ipsen

National Cancer Institute (NCI)

Sanofi

University of California, San Francisco

University of Vienna

Organization Involved with Phase 2 Indications (22)

Amgen

Chinese Academy of Medical Sciences

Cornell University

Eastern Cooperative Oncology Group

ECOG-ACRIN Cancer Research Group

Grupo Espanol de Tumores Neuroendocrinos (GETNE)

Harvard University

Istituto Nazionale per lo Studio e la Cura dei Tumori

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Institutes of Health (NIH)

Northwestern University

Ochsner Health System

Ohio State University

Schering-Plough

Tsinghua University

University of Cambridge

University of London

University of Milan

University of Paris

University of South Florida

University of Texas at Houston

Vanderbilt University

Organization Involved with Phase 1 Indications (4)

Indiana University

Memorial Sloan-Kettering Cancer Center

Threshold Pharmaceuticals

University of Iowa

Organization Involved with Other Experimental Indications (1)

Johns Hopkins University

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.